Personalized drug test aims to outsmart refractory brain tumors

NCT ID NCT06804655

Not yet recruiting Knowledge-focused Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a lab technique called pharmacoscopy that analyzes a patient's tumor tissue to find which drugs might work best for them. It includes 40 adults with various aggressive or rare brain tumors that have not responded to standard treatments. The main goal is to see if the test can provide a usable drug recommendation within 10 days and if doctors can then start that treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pharmacoscopy (ex vivo drug profiling test)
What this could lead to: If successful, this approach could help doctors choose personalized treatments for patients with brain tumors that have not responded to standard therapy.
What could go wrong: This is a small, early-phase feasibility study. It may not show that the drug selection improves outcomes, and the test may fail to produce results in time for some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN (NERVOUS SYSTEM) CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system neoplasm diffuse glioma, H3 G34 mutant ependymoma glioblastoma glioma IDH-mutant anaplastic astrocytoma medulloblastoma meningioma neoplasm nervous system cancer Neurologic Manifestations oligodendroglioma primary brain neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN (NERVOUS SYSTEM) CANCERS EPENDYMOMA GLIOBLASTOMA GLIOMA MEDULLOBLASTOMA MENINGIOMA RARE CNS PRIMARY TUMORS RARE PRIMARY BRAIN TUMORS

Contacts and locations

Locations

Cantonal Hospital St Gallen

Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
University Hospital Basel

Basel, Basel-Landschaft, 4021, Switzerland
University Hospital Zurich

Zurich, Canton of Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.